论文部分内容阅读
灯盏花注射液是90年代活血化瘀的单味中成药制剂,近年来多用于治疗缺血性心、脑血管疾病。现将我院近3年期间用云南灯盏花注射液治疗的60例脑梗塞,并设56例低分子右旋糖酐液加维脑路通治疗为对照组的临床观察报告如下。 1 资料与方法 1.1 一般资料 灯盏花注射液治疗组共60例脑梗塞患者,均为我院住院患者。其中男38例,女22例,年龄46～74岁。对照组为随机抽取的同期脑梗塞住院患者,共56例,其中男35例,女21例,年龄42～73岁。全部病例均根据第二届全国脑血管病会议拟定的诊断标准,并做脑CT检查确诊。两组患者治疗前年龄、病程、神经功能缺损平均积分经统计学处理P>0.05,无显著差异。
Breviscapine Injection is a single Chinese medicine in the 90s blood circulation, and more in recent years for the treatment of ischemic heart and cerebrovascular disease. Now in our hospital during the past 3 years with Yunnan Erigeron Injection treatment of 60 cases of cerebral infarction, and 56 cases of low molecular dextran solution Jiaweiluotong treatment for the control group clinical observations are as follows. 1 Materials and Methods 1.1 General Information Breviscapine injection group of 60 patients with cerebral infarction, hospital patients were in our hospital. There were 38 males and 22 females, aged 46-74 years old. Control group were randomized patients with cerebral infarction in the same period, a total of 56 cases, 35 males and 21 females, aged 42 to 73 years. All cases were diagnosed according to the diagnostic criteria formulated by the 2nd National Cerebrovascular Disease Conference and brain CT examination. Two groups of patients before treatment, duration, neurological deficit average score by statistical analysis P> 0.05, no significant difference.